A new drug to potentially treat depression and neurodegenerative diseases, such as dementia or Parkinson’s, is being ...

which looked at the drug in Alzheimer’s disease. But Axovant said it will continue to develop nelotanserin to treat hallucinations in patients with Parkinson’s disease dementia, and is ...

As the second oral therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer’s disease during the past decade, ZUNVEYL demonstrates a potentially better safety ...

Dementia with Lewy bodies ... so the discovery that commonly used drugs may reduce the risk of the disease is a beacon of hope for patients and their carers. The main finding of the observational ...

(“Alpha”) of the improved new drug ZUNVEYL ... in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of ...

Experts from the University of Nottingham found that there was nearly a 50 per cent increased risk of dementia among patients aged 55 and over who had used strong anticholinergic medication daily ...

The study, carried out by experts from the University of Nottingham and funded by the National Institute for Health Research (NIHR), found that there was nearly a 50% increased risk of dementia among ...